research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
Search
for
Sort by
Research
330-360 / 1000+ results 
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.
research Editorial: Exploring innovative therapies for rare inflammatory skin diseases
New therapies for rare skin diseases show promise but need more research.
research Ferulic acid promotes hair growth via estrogen receptor alpha activation in cultured human dermal papilla cells
Ferulic acid may help hair grow by activating certain receptors in cells.
research Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA
More severe alopecia areata can lower quality of life.
research Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
Upadacitinib improved multiple immune-related conditions in one patient.
research Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review
Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
research Evidence Synthesis Gone Awry: The Perils of Aggregating Ineffective or Unsafe Doses in Alopecia Areata Reviews
Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.
research Alopecia Areata Associated with Dupilumab: A Case Report and Literature Review
Dupilumab may cause hair loss, so patients should be monitored.
research Turning JAK STATic, a peek into the future of dermatology therapeutics
JAK inhibitors show promise for treating skin diseases effectively and safely.
research Common Causes of Hair Loss and Their Treatment Options
Various treatments exist for hair loss, but no definitive solution.
research An Overview about Alopecia Areata Etiopathogenesis, Diagnosis, and Management: Review Article
Alopecia areata is a hair loss condition caused by immune factors and can be treated with JAK inhibitors.
research A retrospective review of paediatric alopecia areata cases seen in a tertiary institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
research Under Development JAK Inhibitors for Dermatologic Diseases
New JAK inhibitor drugs show promise for treating skin diseases but need more research on safety and effectiveness.
research Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
Biologics and JAK inhibitors may improve treatment for scarring alopecias.
research Alopecia Areata: The Clinician and Patient Voice
Alopecia areata causes unpredictable hair loss and emotional distress, with no cure and limited treatment options.
research Case Report: Compound heterozygous variants in LSS and TSPEAR genes causing hypotrichosis type 14 complicated with ectodermal dysplasia type 14
A child has a rare hair and skin disorder due to specific gene variants, suggesting broader genetic testing is needed.
research Treatment of Alopecia Areata and Its Numerous Possibilities: A Literature Review
Alopecia areata treatment should be personalized, using topical or systemic therapies based on severity, with promising options like JAK inhibitors needing more research.
research THE PATTERN AND CLINICAL PROFILE OF ALOPECIA AREATA. PANORAMIC REVIEW: UPDATE AND ADVANCES ON ETIOPATHOGENESIS, ASSOCIATED FACTORS, DIAGNOSIS, COMPLICATIONS, MANAGEMENT AND PROGNOSIS IN TREATMENT 2023
Alopecia areata causes sudden hair loss, has genetic links, and can be managed but not cured.
research Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
A protein called EGFR protects hair follicle stem cells, and when it's disrupted, hair follicles can be damaged, but blocking certain pathways can restore hair growth.
research Drug Armamentarium for alopecia areata
No cure exists for alopecia areata, and treatments are personalized.
research Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs
The Middle East and Africa need better data, treatment consensus, and support for Alopecia Areata.
research Longitudinal clinical course, treatment outcomes, and relapse patterns in alopecia areata: a prospective cohort study
Baseline severity and relapse history affect alopecia areata treatment and recurrence.
research Treatment of frontal fibrosing alopecia: literature review 2020-2025
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
research Folliculitis Decalvans: A Review of Current Treatment Modalities
Current treatments for folliculitis decalvans include antibiotics, isotretinoin, and potential new therapies like botulinum toxin A and PRP.
research Alopecia areata
Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
research Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.